Daxor Corporation (DXR)
NASDAQ: DXR
· Real-Time Price · USD
10.79
-0.24 (-2.18%)
At close: Aug 14, 2025, 3:59 PM
10.61
-1.67%
After-hours: Aug 14, 2025, 04:26 PM EDT
Company Description
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing.
The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.
The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973.
Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
Daxor Corporation
| Country | United States |
| IPO Date | Jul 25, 1983 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Michael Richard Feldschuh |
Contact Details
Address: 109 Meco Lane Oak Ridge, Tennessee United States | |
| Website | https://www.daxor.com |
Stock Details
| Ticker Symbol | DXR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000027367 |
| CUSIP Number | 239467103 |
| ISIN Number | US2394671034 |
| Employer ID | 13-2682108 |
| SIC Code |
Key Executives
| Name | Position |
|---|---|
| Michael Richard Feldschuh | Chairman, President & Chief Executive Officer |
| Robert J. Michel CPA, CPA, M.B.A. | Chief Financial Officer, Chief Compliance Officer & Corporate Secretary |
| Dr. John Lynn Jefferies FACC, M.B.A., M.D., M.P.H. | Chief Medical Officer |
| Jonathan Adam Feldschuh | Chief Scientific Officer & Director |
| Kathryn A. Kornafel | Senior Vice President of Marketing & Commercial Development |
| Linda Cooper | Vice President of Development & Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 07, 2025 | 8-K | Current Report |
| Jul 24, 2025 | N-2/A | [Amend] Filing |
| Jul 24, 2025 | N-CEN/A | [Amend] Filing |
| Jul 24, 2025 | N-CEN/A | [Amend] Filing |
| Jul 01, 2025 | 8-K | Current Report |
| Jun 26, 2025 | 4 | Filing |
| Jun 26, 2025 | 4 | Filing |
| Jun 26, 2025 | 4 | Filing |
| Jun 26, 2025 | 4 | Filing |
| Jun 13, 2025 | 40-17F2 | Filing |